Loading
PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling.
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants, naming Venetoclax.
In plain words · PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.
PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling.
No product in this corpus aims at PLCG2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PLCG2: RNA tissue enhanced (lymphoid tissue 42 nTPM); high antibody staining in 8 normal tissues; highest cancer staining lymphoma (11 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PLCG2 tissue; Open Targets ENSG00000197943 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Ohta et al, FEBS Lett, 1988, "Complete cDNA encoding a putative phospholipase C from transformed human lymphocytes". Source.
Sources: HGNC HGNC:9066 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16885 (protein name, function text, keywords and locations (REST API)); CIViC gene PLCG2 (3 evidence items, 0 assertions, 3 variants; diseases: Chronic Lymphocytic Leukaemia (GraphQL API, CC0))
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling. Location: Membrane raft (UniProt). Locus 16q24.1 (HGNC).
RNA: tissue enhanced (lymphoid tissue 42 nTPM), detected in many normal tissues.
Medium: Gallbladder, Testis.
RNA cancer enhanced: Kidney Chromophobe 246 pTPM.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PLCG2" OR ABSTRACT:"PLCG2" OR TITLE:"phospholipase C gamma 2" OR ABSTRACT:"phospholipase C gamma 2" OR TITLE:"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2" OR ABSTRACT:"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PLCG2, not a curated reading list.
Shares Inflammation & NF-κB, Mantle cell lymphoma, Chronic lymphocytic leukaemia, CIViC.
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, CIViC, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, CIViC, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, CIViC, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, CIViC, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), CIViC, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), CIViC, Non-Hodgkin lymphoma (all types).